Osteogenesis Imperfecta (OI) Clinical Trials and Treatments

Osteogenesis imperfecta (OI) is a genetic disorder affecting type I collagen synthesis or structure, resulting in defective bone matrix and severe bone fragility. Type I collagen constitutes approximately 90% of bone organic matrix; defects cause profound bone quality and quantity abnormalities, leading to propensity for fractures with minimal trauma. Severity varies greatly: Type I (mild) features normal height, blue sclera, and fractures beginning in childhood; Type II (perinatally lethal) features severe skeletal deformities and intrauterine or early postnatal death; Type III (progressive) features severe skeletal deformities, growth retardation, and progressive disabilities; Type IV features variable severity.

The most common symptoms of Osteogenesis Imperfecta include Frequent bone fractures, often from minor trauma or spontaneously, Delayed bone healing and poor fracture callus formation, Bowing of long bones and growth retardation, Progressive hearing loss in many patients, Dental abnormalities and enamel defects, among others. Osteogenesis Imperfecta affects approximately 1 in 10,000 to 1 in 20,000 people. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Osteogenesis Imperfecta from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Sclerostin inhibitors aim to build new bone rather than only slow bone loss. Ultragenyx reported on December 29, 2025 that its 2 Phase 3 studies of setrusumab, Orbit and Cosmic, did not reach statistical significance on their main goal of fewer fractures, though both raised bone density.

As of October 21, 2026, no current FDA drug label names Osteogenesis Imperfecta as a condition the drug treats.

Osteogenesis Imperfecta is caused by variants in any of many genes, most often COL1A1, COL1A2, IFITM5, CRTAP, P3H1 and SERPINF1. COL1A1 and COL1A2 account for about 90% of cases and are dominant; the rarer recessive forms involve collagen-processing genes.

It follows autosomal dominant or recessive depending on gene inheritance. The condition affects approximately 1 in 10,000 to 1 in 20,000 people. A multigene panel identifies the cause in most families.

Yes. Osteogenesis Imperfecta can be caused by variants in many different genes (COL1A1, COL1A2, IFITM5, CRTAP, P3H1 and SERPINF1 are among the most common), so testing is usually a multigene panel or exome sequencing rather than one gene at a time. COL1A1 and COL1A2 account for about 90% of cases and are dominant; the rarer recessive forms involve collagen-processing genes.

It follows autosomal dominant or recessive depending on gene inheritance.

Knowing the exact gene matters: it decides which trials a patient qualifies for and which relatives should be tested. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Osteogenesis Imperfecta clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Osteogenesis Imperfecta clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.